Table 4.
Summary of the adverse events during the intervention
| ADVERSE EVENTS | IG 1 (n=27) | IG 2 (n=27) | IG 3 (n=21) | P-value | ||
|---|---|---|---|---|---|---|
| No. (%) of participants | No. (%) of participants | No. (%) of participants | IG1xIG2 | IG1xIG3 | IG2xIG3 | |
| Fatigue | 14 (51.9) | 6 (22.2) | 9 (42.9) | 0.0473 | 0.5734 | 0.2089 |
| Headache | 8 (29.6) | 5 (18.5) | 5 (23.8) | 0.5256 | 0.7502 | 0.7291 |
| Decrease in performance | 9 (33.3) | 4 (14.8) | 4 (19.0) | 0.2021 | 0.3377 | 0.7155 |
| Concentration disorder | 6 (22.2) | 2 (7.4) | 1 (4.8) | 0.2501 | 0.118 | >0.99 |
| Appetite (e.g., sweet, alcohol) | 17 (63.0) | 19 (70.4) | 12 (57.1) | 0.7734 | 0.7701 | 0.3775 |
| Hunger | 20 (74.1) | 14 (51.9) | 15 (71.4) | 0.1581 | >0.99 | 0.2369 |
| Uncomfortable feeling of fullness or overeating | 14 (51.9) | 7 (25.9) | 17 (81.0) | 0.0929 | 0.0666 | 0.0004 |
| Any other adverse events | 5 (15.5) | 3 (11.1) | 2 (9.5) | 0.704 | 0.4452 | >0.99 |